McKean-Cowdin R, Feigelson H S, Pike M C, Coetzee G A, Kolonel L N, Henderson B E
Department of Preventive Medicine, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles 90033-0800, USA.
Cancer Res. 2001 Feb 1;61(3):848-9.
Common variants among genes coding for enzymes in sex steroid biosynthetic pathways may influence the risk of endometrial cancer. We examined the association between endometrial cancer risk and estrogen replacement therapy (ERT) by CYP17 genotype using 51 incident cases and 391 randomly selected controls from a multiethnic cohort in Hawaii and Los Angeles, California. The relative risk of endometrial cancer was calculated for ever use versus never use of ERT by CYP17 genotype (TT, TC, and CC). We found that women who reported ever taking ERT were more than twice as likely to develop endometrial cancer as women who never took ERT [odds ratio (OR), 2.24; 95% confidence interval (CI), 1.19-4.23]. Among these women, the risk of endometrial cancer was higher for women homozygous for the CYP17 T allele (OR, 4.10; 95% CI, 1.64-10.3), but not for women with the C allele (OR, 1.31; 95% CI, 0.53-3.21). These preliminary findings suggest that CYP17 or other variants in estrogen biosynthesis or metabolism pathways may be potential markers of endometrial cancer susceptibility due to ERT.
性类固醇生物合成途径中编码酶的基因的常见变异可能会影响子宫内膜癌的风险。我们使用来自夏威夷和加利福尼亚州洛杉矶的一个多民族队列中的51例新发病例和391名随机选择的对照，通过CYP17基因型研究了子宫内膜癌风险与雌激素替代疗法（ERT）之间的关联。根据CYP17基因型（TT、TC和CC）计算曾经使用ERT与从未使用ERT的子宫内膜癌相对风险。我们发现，报告曾经接受ERT的女性患子宫内膜癌的可能性是从未接受ERT的女性的两倍多[比值比（OR），2.24；95%置信区间（CI），1.19 - 4.23]。在这些女性中，CYP17 T等位基因纯合的女性患子宫内膜癌的风险更高（OR，4.10；95% CI，1.64 - 10.3），但携带C等位基因的女性则不然（OR，1.31；95% CI，0.53 - 3.21）。这些初步发现表明，CYP17或雌激素生物合成或代谢途径中的其他变异可能是ERT导致子宫内膜癌易感性的潜在标志物。
